Table 3.
Clinical features for the patients receiving carbapenems or other antibiotics on day 0
| Missing data | Carbapenems n = 81 | Other AIT n = 278 | p value | |
|---|---|---|---|---|
| Severity criteria at day 0 | ||||
| SOFA score, median [IQR] | 4/9 | 5 [3–7] | 5 [3–7] | NS |
| Respiratory failure*, n (%) | 0 | 32 (40) | 103 (37) | NS |
| Cardiovascular failure*, n (%) | 0 | 39 (48) | 123 (44) | NS |
| Renal failure*, n (%) | 0 | 14 (17) | 53 (19) | NS |
| Septic shock, n (%) | 0 | 29 (36) | 81 (29) | NS |
| Acute respiratory distress syndrome, n (%) | 0 | 11 (14) | 26 (9) | NS |
| Main reasons for anti-infective therapy at day 0 | ||||
| Empirical therapy, n (%) | 0 | 67 (83) | 232 (83) | NS |
| Intra-abdominal infection, n (%) | 1/5 | 55 (69) | 155 (57) | NS |
| Pneumonia, n (%) | 2/6 | 7 (9) | 39 (14) | NS |
| Bacteraemia, n (%) | 2/3 | 6 (8) | 39 (14) | NS |
| Catheter-related infection, n (%) | 2/3 | 2 (3) | 7 (3) | NS |
| Urinary tract infection, n (%) | 2/4 | – | 9 (3) | NS |
| Skin and soft tissue infection, n (%) | 2/3 | – | 2 (1) | NS |
| Most frequently prescribed anti-infective agents at day 0 | ||||
| Beta-lactams, n (%) | 0 | 81 (100) | 191 (69) | < 0.001 |
| Aminoglycosides, n (%) | 0 | 41 (51) | 79 (28) | < 0.001 |
| Anti-Gram-positive agents, n (%) | 0 | 20 (30) | 30 (11) | < 0.01 |
| Antifungal agents, n (%) | 0 | 20 (25) | 33 (12) | < 0.01 |
| Azoles, n (%) | 0 | 18 (22) | 28 (10) | < 0.01 |
| Echinocandins, n (%) | 0 | 1 (1) | 4 (1) | NS |
| Duration of AIT, days, median [IQR] | 3/8 | 7 [3–15] | 4 [1–10] | < 0.01 |
| ICU length of stay, days, median [IQR] | 0 | 14 [4–27] | 8 [3–19] | < 0.05 |
| ICU readmission, n (%) | 0/1 | 5 (6) | 22 (8) | NS |
| Hospital mortality, n (%) | 0 | 22 (27) | 71 (26) | NS |
| Time to death, days, median [IQR] | 0 | 31 [7–43] | 3 [1–19] | < 0.01 |
NS non-significant
*According to the definition of the SOFA score